Investment firm Prairie Fire Capital led a $18m funding round in GoodCell, a biotechnology company. "Traditional risk factors such as age, weight and chronic conditions are important, but offer an incomplete picture for assessing susceptibility to an ailment. Mounting evidence suggests that accumulated genetic variations in our cells play a significant role, as well. Moreover, the ability to evaluate and measure cell quality has the potential to improve quality and consistency of process while potentially reducing costs associated with the manufacturing of cellular products prior to clinical application," Brad Hamilton, GoodCell Founder and Chief Science Officer.